The COVID-19 pandemic has accelerated the adoption of decentralized clinical trials, which involves offering services and technologies to improve convenience for patients participating in research. Decentralized clinical trials have the potential to enhance patient participation in research overall but there are considerations health systems and pharmaceutical companies should keep in mind as they look to adopt these clinical trials.  In the newest episode of Healthcare Insider, Bryce Davis, senior director of Veeva Engage at Veeva Systems, discusses these topics and more.